5 stories mentioning PGNYUpdated 3d ago
Every FINWIRES story that references PGNY, newest first.
Progyny (PGNY) shares were down 2.5% in afternoon trading on Tuesday after Barclays downgraded the company's stock to equal-weight from overweight, and adjusted the price target to $34 from $27.Trading volume stood at more than 950,000 shares against a daily average of about 1.5 million.Price: $30.71, Change: $-0.88, Percent Change: -2.79%
Progyny (PGNY) has an average rating of buy and mean price target of $34, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Progyny (PGNY) board authorized a stock buyback plan worth up to $200 million of its common shares, the company said Tuesday.The buyback plan will be financed using the company's available cash resources, Progyny added.Price: $25.37, Change: $+0.48, Percent Change: +1.95%
Progyny (PGNY) has an average rating of Buy and mean price target of $29.55, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Progyny (PGNY) said Thursday it released a fully insured supplemental fertility and family building plan for small U.S. employers.The medical benefit platform uses a fixed per-employee-per-month pricing model to help establish predictable healthcare costs for smaller corporate clients, the company said.The offering provides support across fertility and women's health, including IVF, IUI, genetic testing, and coaching for pregnancy, postpartum, parenting, and menopause, Progyny said.The plan will be available for employers to implement in their 2027 plan years.Price: $17.63, Change: $+0.24, Percent Change: +1.38%
